Notice of Intent to Sole Source

The Centers for Disease Control and Prevention intends to award one sole source firm fixed price contract modification under contract 75D30123D16111 with Sanofi Pasteur Inc. for the addition of the ACIP recommended Nirsevimab vaccine. The National Center for Immunization and Respiratory Diseases (NCIRD) awarded multiple indefinite delivery, indefinite quantity (IDIQ) one-year contracts for the purchase of standard commercial pediatric vaccines, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA). The vaccines awarded under these contracts will be purchased for NCIRD's immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and VFC, as established pursuant to Section 13631of the Omnibus Budget Reconciliation Act of 1993. Orders for the vaccines on these contracts are ordered through the NCIRD electronic vaccine ordering system. The initial contracts, awarded in April 2023 were established to support public sector ACIP recommended routine vaccinations for children. The Sanofi contract will be modified to support purchase of Nirsevimab for prevention of respiratory syncytial virus (RSV) in children following CDC's Advisory Committee on Immunization Practices (ACIP) approval and accompanying VFC resolution on August 3, 2023. Nisevimab from Sanofi is the only product currently licensed for prevention of RSV in infants and Sanofi is the only manufacturer with an FDA-approved license for this product. CDC's current contract with Sanofi will be modified to include a sufficient quantity of doses required to support purchase of Nirsevimab to administer to VFC eligible newborns and infants. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1 and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within seven (7) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Christina McMichael at wpn6@cdc.gov by 5:00 PM EST on August 15, 2023.